dowjones.com reports to: After a weak start to the year of the PMI in the manufacturing sector suggests more of a stabilization of the second largest economy in the world there …
dowjones.com continues: After a weak start to the year of the PMI in the manufacturing sector indicates a stabilization of the second largest economy in the world through more …
More news from dowjones.com: the Issuer is solely responsible for the content of this announcement Read more …
These reports further dpa.de: Basilea cancer drug candidate BAL101553 shows in Phase 1 study first evidence of anti-tumor activity more …
These hugingroup.com continues: * Results from recent completed phase 1 trial presented at ASCO presents Basel, June 2nd, 2014 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announces that on in Chicago, USA, held annual conference of the American Society of Clinical Oncology (ASCO) Phase 1 study results to her in the Development located cancer drug BAL101553 were presented. In the study, the maximum tolerated dose was determined. In addition, the study provided the first clinical evidence of anti-tumor effect. Read more …
No comments:
Post a Comment